{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-26-020934","form_type":"8-K","ticker":"PDSB","cik":"0001472091","company_name":"PDS Biotechnology Corp","filed_at":"2026-05-13T11:05:28+00:00","discovered_at":"2026-05-13T11:10:00.319675+00:00","generated_at":"2026-05-13T11:13:14.355070+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"PDS Biotech Q1 net loss $7.3M ($0.13/sh); VERSATILE-003 amended with PFS endpoint","bullets":["Net loss $7.3M ($0.13 per share) vs $8.5M ($0.21) YoY; revenue not reported.","R&D expenses $3.5M, down from $5.8M; cash $21.7M at March 31.","VERSATILE-003 Phase 3 amended to add PFS as interim primary endpoint, reducing enrollment; patients already enrolled continue.","PDS01ADC mCRC trial: 77.8% ORR and ~85% 24-month survival; mCRPC trial: median PFS 9.6 months.","New US and Japan patents granted for PDS0101, extending market protection into 2040s."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-020934","json":"https://secwatch.observer/filing/0001140361-26-020934.json","markdown":"https://secwatch.observer/filing/0001140361-26-020934.md","text":"https://secwatch.observer/filing/0001140361-26-020934.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1472091/000114036126020934/0001140361-26-020934-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1472091/000114036126020934/ef20073195_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-13T11:13:14.355070+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a4e7e9485950a41c10bbc5800f41508323705e9c","claim":"PDS Biotechnology Corp reported the quarter ended March 31, 2026 results: net income net loss of approximately $7.3 million, EPS $0.13 per basic and diluted share.","evidence_excerpt":"Reported net loss for the quarter ended March 31, 2026, was approximately $7.3 million, or $0.13 per basic and diluted share","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1472091/000114036126020934/0001140361-26-020934-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2026"},{"label":"Net income","value":"net loss of approximately $7.3 million"},{"label":"EPS","value":"$0.13 per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}